首页 > 最新文献

American journal of cardiovascular disease最新文献

英文 中文
Myocarditis presentation following COVID-19 virus infection versus COVID-19 vaccination. 新冠肺炎病毒感染与新冠肺炎疫苗接种后的心肌炎表现。
IF 1.3 Pub Date : 2022-10-15 eCollection Date: 2022-01-01
Usha Yendrapalli, Ali Hassoun, Roderick M Zalamea, Abdulwahab Hritani

Coronavirus disease 2019 (COVID-19) vaccine-induced cardiac injury has recently emerged as a major public health concern around the globe. There are reported cases of COVID-19 vaccine-induced myocarditis, but they are generally extremely rare and mild. In contrast, COVID-19 infection can cause acute cardiac injury with poor prognosis and high mortality rates. Herein, we describe the difference in patients' presentation by comparing two cases of myocarditis. One after contracting COVID-19 virus infection with a severe clinical course, and the other patient developed myocarditis post-COVID-19 vaccine.

2019冠状病毒病(新冠肺炎)疫苗引起的心脏损伤最近已成为全球主要的公共卫生问题。据报道,有新冠肺炎疫苗引起的心肌炎病例,但通常极为罕见和轻微。相比之下,新冠肺炎感染可导致急性心脏损伤,预后不良,死亡率高。在此,我们通过比较两例心肌炎来描述患者表现的差异。一名患者在感染新冠肺炎病毒后出现严重临床症状,另一名患者接种了新冠肺炎后心肌炎疫苗。
{"title":"Myocarditis presentation following COVID-19 virus infection versus COVID-19 vaccination.","authors":"Usha Yendrapalli,&nbsp;Ali Hassoun,&nbsp;Roderick M Zalamea,&nbsp;Abdulwahab Hritani","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) vaccine-induced cardiac injury has recently emerged as a major public health concern around the globe. There are reported cases of COVID-19 vaccine-induced myocarditis, but they are generally extremely rare and mild. In contrast, COVID-19 infection can cause acute cardiac injury with poor prognosis and high mortality rates. Herein, we describe the difference in patients' presentation by comparing two cases of myocarditis. One after contracting COVID-19 virus infection with a severe clinical course, and the other patient developed myocarditis post-COVID-19 vaccine.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677185/pdf/ajcd0012-0272.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10278094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Twelve months clinical outcomes of ultrathin strut sirolimus-eluting stent in real-world Indian patients with coronary artery disease. 超薄支架西罗莫司洗脱支架在现实世界印度冠状动脉疾病患者中的十二个月临床结果
IF 1.3 Pub Date : 2022-10-15 eCollection Date: 2022-01-01
Prakash Ajmera, Ramesh Pothineni, Kamal Kumar Chawla, Sai Sudhakar Mantravadi, Pankaj Jariwala, Vinod Vijan, Vikrant Vijan

Purpose: Although the field of interventional cardiology has witnessed extraordinary progression, the search of an ideal coronary drug-eluting stent is still going on. Tetriflex (Sahajanand Medical Technologies Limited, Surat, India) is a latest generation biodegradable polymer-coated ultrathin (60 µm) sirolimus-eluting stent (SES) with unique Long Dual Z-link (LDZ) design. The present registry reports the 12 months clinical follow-up results of Tetriflex SES in unselected, real-world patients with coronary artery disease (CAD).

Methods: This was an investigator-initiated, retrospective, multi-center, single-arm, observational registry conducted in India between March-2017 and March-2018. The registry included 1269 consecutive patients with CAD who underwent implantation of at least one Tetriflex SES. The primary outcome was considered as target lesion failure (TLF), which was a composite of cardiac death, target-vessel myocardial infarction (TV-MI) and clinically-driven target lesion revascularisation (CD-TLR) at 12 months follow-up. The safety outcome, at 12 months follow-up, was stent thrombosis.

Results: Mean age of patients was 54.99±10.80 years. Among all, 36.6% patients had diabetes and 51.7% patients had multi-vessel disease. A total of 1515 lesions were treated with 1682 Tetriflex SES of which 73.2% lesions were complex B2/C type and 14.7% were totally occluded. At 12 months, the cumulative incidence of TLF was 5.75% comprising 0.8% cardiac death, 3.20% TV-MI and 1.72% CD-TLR. All the incidences of definite/probable stent thrombosis (n = 4, 0.32%) were reported within 30 days of the index procedure. Twelve-month cumulative incidence of TLF in diabetic subgroup was 7.10%.

Conclusion: Twelve months clinical follow-up results of an ultrathin (60 µm), biodegradable polymer-coated Tetriflex SES, with unique LDZ-link, further clarify its safety and effectiveness in real-world, unselected Indian patients.

目的:虽然介入心脏病学领域取得了非凡的进展,但理想的冠状动脉药物洗脱支架的寻找仍在继续。Tetriflex (Sahajanand Medical Technologies Limited, Surat, India)是最新一代生物可降解聚合物涂层超薄(60µm)西罗莫司洗脱支架(SES),具有独特的长双Z-link (LDZ)设计。目前的注册报告了Tetriflex SES在未选择的现实世界冠心病(CAD)患者中12个月的临床随访结果。方法:这是2017年3月至2018年3月在印度进行的一项研究者发起的、回顾性的、多中心的、单臂的观察性登记。登记包括1269例连续接受至少一个Tetriflex SES植入的CAD患者。主要结局被认为是靶病变失败(TLF),这是12个月随访时心脏死亡、靶血管心肌梗死(TV-MI)和临床驱动的靶病变血运重建(CD-TLR)的复合结果。在12个月的随访中,安全性结果为支架血栓形成。结果:患者平均年龄54.99±10.80岁。其中糖尿病患者占36.6%,多血管病变患者占51.7%。1682例Tetriflex SES共治疗病变1515例,其中B2/C复合病变73.2%,完全闭塞14.7%。12个月时,TLF的累积发生率为5.75%,其中心源性死亡0.8%,TV-MI 3.20%, CD-TLR 1.72%。所有确定/可能的支架血栓发生率(n = 4, 0.32%)均在指标手术后30天内报告。糖尿病亚组12个月累积TLF发生率为7.10%。结论:具有独特LDZ-link的超薄(60µm)可生物降解聚合物包被Tetriflex SES的12个月临床随访结果进一步阐明了其在现实世界中未选择的印度患者中的安全性和有效性。
{"title":"Twelve months clinical outcomes of ultrathin strut sirolimus-eluting stent in real-world Indian patients with coronary artery disease.","authors":"Prakash Ajmera,&nbsp;Ramesh Pothineni,&nbsp;Kamal Kumar Chawla,&nbsp;Sai Sudhakar Mantravadi,&nbsp;Pankaj Jariwala,&nbsp;Vinod Vijan,&nbsp;Vikrant Vijan","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Purpose: </strong>Although the field of interventional cardiology has witnessed extraordinary progression, the search of an ideal coronary drug-eluting stent is still going on. Tetriflex (Sahajanand Medical Technologies Limited, Surat, India) is a latest generation biodegradable polymer-coated ultrathin (60 µm) sirolimus-eluting stent (SES) with unique Long Dual Z-link (LDZ) design. The present registry reports the 12 months clinical follow-up results of Tetriflex SES in unselected, real-world patients with coronary artery disease (CAD).</p><p><strong>Methods: </strong>This was an investigator-initiated, retrospective, multi-center, single-arm, observational registry conducted in India between March-2017 and March-2018. The registry included 1269 consecutive patients with CAD who underwent implantation of at least one Tetriflex SES. The primary outcome was considered as target lesion failure (TLF), which was a composite of cardiac death, target-vessel myocardial infarction (TV-MI) and clinically-driven target lesion revascularisation (CD-TLR) at 12 months follow-up. The safety outcome, at 12 months follow-up, was stent thrombosis.</p><p><strong>Results: </strong>Mean age of patients was 54.99±10.80 years. Among all, 36.6% patients had diabetes and 51.7% patients had multi-vessel disease. A total of 1515 lesions were treated with 1682 Tetriflex SES of which 73.2% lesions were complex B2/C type and 14.7% were totally occluded. At 12 months, the cumulative incidence of TLF was 5.75% comprising 0.8% cardiac death, 3.20% TV-MI and 1.72% CD-TLR. All the incidences of definite/probable stent thrombosis (n = 4, 0.32%) were reported within 30 days of the index procedure. Twelve-month cumulative incidence of TLF in diabetic subgroup was 7.10%.</p><p><strong>Conclusion: </strong>Twelve months clinical follow-up results of an ultrathin (60 µm), biodegradable polymer-coated Tetriflex SES, with unique LDZ-link, further clarify its safety and effectiveness in real-world, unselected Indian patients.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677186/pdf/ajcd0012-0262.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40702404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-hospital complications associated with total artificial heart implantation in the United States between 2004 to 2011. 2004年至2011年美国全人工心脏植入相关的住院并发症
IF 1.3 Pub Date : 2022-10-15 eCollection Date: 2022-01-01
Ahmed K Pasha, Justin Z Lee, Hem Desai, Mehrtash Hashemzadeh, Mohammad Reza Movahed

Objective: Total artificial heart (TAH) utilization has increased over the recent years. The goal of this study was to evaluate the trend of artificial hearts used in the USA with its associated morbidity and mortality based on a large in-hospital database.

Materials and methods: Using a very large nationwide inpatient samples (NIS) database, we used ICD-9 code for a total artificial heart. We evaluated the utilization of this device over the years studied. Furthermore, we evaluated any associated complications and mortality in patients receiving this device.

Results: From 2004 until 2011, the rate of total artificial heart implants increased over the years from 5 in 2004 to the highest of 26 in 2011 across the United State. TAH was insesrted in 75 patients. Death was reported in 22 patients (29.3%). Acute renal failure was the most common complication (69.3%). This is followed by post-operative infectious complications (28.0%), acute renal failure requiring dialysis (16%), bleeding complications requiring blood transfusion (14.7%) respiratory complications (6.7%), and stroke/TIA (4.0%). There was no post-operative deep vein thrmobosis or pulmonary embolism.

Conclusions: The use of total artificial heart has increased in the United State steadily with substantial morbidity and mortality associated with this device.

目的:近年来全人工心脏(TAH)的使用率有所上升。本研究的目的是基于一个大型医院内数据库,评估美国人工心脏的使用趋势及其相关的发病率和死亡率。材料和方法:使用一个非常大的全国住院患者样本(NIS)数据库,我们使用ICD-9编码进行全人工心脏。我们在研究期间评估了该装置的使用情况。此外,我们评估了接受该装置的患者的任何相关并发症和死亡率。结果:从2004年到2011年,全美人工心脏植入率从2004年的5例逐年上升到2011年最高的26例。75例患者植入TAH。死亡22例(29.3%)。急性肾功能衰竭是最常见的并发症(69.3%)。其次是术后感染并发症(28.0%)、需要透析的急性肾衰竭(16%)、需要输血的出血并发症(14.7%)、呼吸系统并发症(6.7%)和卒中/TIA(4.0%)。术后无深静脉血栓形成或肺栓塞。结论:全人工心脏的使用在美国稳步增加,与该装置相关的发病率和死亡率都很高。
{"title":"In-hospital complications associated with total artificial heart implantation in the United States between 2004 to 2011.","authors":"Ahmed K Pasha,&nbsp;Justin Z Lee,&nbsp;Hem Desai,&nbsp;Mehrtash Hashemzadeh,&nbsp;Mohammad Reza Movahed","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Total artificial heart (TAH) utilization has increased over the recent years. The goal of this study was to evaluate the trend of artificial hearts used in the USA with its associated morbidity and mortality based on a large in-hospital database.</p><p><strong>Materials and methods: </strong>Using a very large nationwide inpatient samples (NIS) database, we used ICD-9 code for a total artificial heart. We evaluated the utilization of this device over the years studied. Furthermore, we evaluated any associated complications and mortality in patients receiving this device.</p><p><strong>Results: </strong>From 2004 until 2011, the rate of total artificial heart implants increased over the years from 5 in 2004 to the highest of 26 in 2011 across the United State. TAH was insesrted in 75 patients. Death was reported in 22 patients (29.3%). Acute renal failure was the most common complication (69.3%). This is followed by post-operative infectious complications (28.0%), acute renal failure requiring dialysis (16%), bleeding complications requiring blood transfusion (14.7%) respiratory complications (6.7%), and stroke/TIA (4.0%). There was no post-operative deep vein thrmobosis or pulmonary embolism.</p><p><strong>Conclusions: </strong>The use of total artificial heart has increased in the United State steadily with substantial morbidity and mortality associated with this device.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677184/pdf/ajcd0012-0278.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40508484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum level of prophylactic antibiotics in cardiac surgery and its implication on surgical site infection (SSI). 心脏外科预防性抗生素血清水平及其对手术部位感染的影响。
IF 1.3 Pub Date : 2022-08-15 eCollection Date: 2022-01-01
Turki B Albacker, Hussain Alqattan, Saeed A Alqahtani, Sultan Alamro, Norah Alsuwaidan, Alhanouf Alaloola, Ahmed Eldemerdash, Bakir Bakir

Background: Surgical site infection in cardiac surgery is still common despite applying preoperative antibiotic prophylaxis as per guidelines. Therefore, the aim of our study was to assess the relationship between perioperative antibiotics serum levels and the incidence of surgical site infection.

Methods: This is a prospective study that included all adult patients who underwent elective coronary artery bypass grafting between June and December 2018. The serum antibiotics levels were measured at 4 different time points. The patients were divided into two groups: The group who developed surgical site infection and the group who did not develop surgical site infection. The serum antibiotics levels were compared between the two groups.

Results: Eighty-seven consecutive patients were enrolled in the study. The overall rate of infection was 17.95% (14/78 patients). High pre-operative HbA1C levels were associated with a higher rate of SSI (SSI 8.46 ± 2.23 vs no SSI 7.28 ± 1.82, P = 0.04). Patients who developed surgical site infection had longer intervals between administration of prophylactic antibiotics and different parts of the procedure than those who did not develop infection T2 (SSI 3.09 ± 1.12 vs no SSI 2.32 ± 0.98, P = 0.004), T3 (SSI 5.74 ± 1.69 vs no SSI 4.68 ± 1.83, P = 0.024) and T4 (SSI 7.35 ± 1.97 vs no SSI 6.01 ± 2.11, P = 0.015).

Conclusion: Prolonging different parts of cardiac surgery procedures could lead to higher risk of infection and better timing of intra-operative re-dosing of prophylactic antibiotics could be guided by measuring intra-operative serum concentrations of these antibiotics.

背景:心脏手术手术部位感染仍然是常见的,尽管术前应用抗生素预防按照指南。因此,我们的研究目的是评估围手术期血清抗生素水平与手术部位感染发生率的关系。方法:这是一项前瞻性研究,纳入了2018年6月至12月期间接受择期冠状动脉旁路移植术的所有成年患者。测定4个不同时间点的血清抗生素水平。患者分为两组:发生手术部位感染组和未发生手术部位感染组。比较两组患者血清抗生素水平。结果:87例连续患者入组研究。总感染率为17.95%(14/78)。术前HbA1C水平高与SSI发生率高相关(SSI 8.46±2.23 vs无SSI 7.28±1.82,P = 0.04)。发生手术部位感染的患者与未发生感染的患者相比,T2 (SSI 3.09±1.12 vs未发生SSI 2.32±0.98,P = 0.004)、T3 (SSI 5.74±1.69 vs未发生SSI 4.68±1.83,P = 0.024)和T4 (SSI 7.35±1.97 vs未发生SSI 6.01±2.11,P = 0.015)使用预防性抗生素的间隔时间更长。结论:延长心脏手术不同部位感染风险较高,可通过术中抗生素浓度测定指导术中预防性抗生素再给药时机。
{"title":"Serum level of prophylactic antibiotics in cardiac surgery and its implication on surgical site infection (SSI).","authors":"Turki B Albacker,&nbsp;Hussain Alqattan,&nbsp;Saeed A Alqahtani,&nbsp;Sultan Alamro,&nbsp;Norah Alsuwaidan,&nbsp;Alhanouf Alaloola,&nbsp;Ahmed Eldemerdash,&nbsp;Bakir Bakir","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Surgical site infection in cardiac surgery is still common despite applying preoperative antibiotic prophylaxis as per guidelines. Therefore, the aim of our study was to assess the relationship between perioperative antibiotics serum levels and the incidence of surgical site infection.</p><p><strong>Methods: </strong>This is a prospective study that included all adult patients who underwent elective coronary artery bypass grafting between June and December 2018. The serum antibiotics levels were measured at 4 different time points. The patients were divided into two groups: The group who developed surgical site infection and the group who did not develop surgical site infection. The serum antibiotics levels were compared between the two groups.</p><p><strong>Results: </strong>Eighty-seven consecutive patients were enrolled in the study. The overall rate of infection was 17.95% (14/78 patients). High pre-operative HbA1C levels were associated with a higher rate of SSI (SSI 8.46 ± 2.23 vs no SSI 7.28 ± 1.82, P = 0.04). Patients who developed surgical site infection had longer intervals between administration of prophylactic antibiotics and different parts of the procedure than those who did not develop infection T2 (SSI 3.09 ± 1.12 vs no SSI 2.32 ± 0.98, P = 0.004), T3 (SSI 5.74 ± 1.69 vs no SSI 4.68 ± 1.83, P = 0.024) and T4 (SSI 7.35 ± 1.97 vs no SSI 6.01 ± 2.11, P = 0.015).</p><p><strong>Conclusion: </strong>Prolonging different parts of cardiac surgery procedures could lead to higher risk of infection and better timing of intra-operative re-dosing of prophylactic antibiotics could be guided by measuring intra-operative serum concentrations of these antibiotics.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490157/pdf/ajcd0012-0233.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33477984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
4 Dimensional XStrain speckle tracking echocardiography: comprehensive evaluation of left ventricular strain and twist parameters in healthy Indian adults during COVID-19 pandemic. 4维XStrain散斑跟踪超声心动图:COVID-19大流行期间印度健康成人左心室应变和扭转参数的综合评价
IF 1.3 Pub Date : 2022-08-15 eCollection Date: 2022-01-01
Akhil Mehrotra, Shubham Kacker, Mohammad Shadab, Naveen Chandra, Alok Kumar Singh

Introduction: 4D XStrain speckle tracking echocardiography (STE) is a feasible newer technology to evaluate the strain and rotational deformation of left ventricle (LV). We aimed to exhaustively present the normal value ranges of LV strain and twist parameter in healthy Indian adults during COVID-19 pandemic and furthermore to analyse their relationship with age and gender.

Method: Study population consisted of 80 adults of 18-60 years (58 men, 22 women), which was arbitrarily divided into two groups: Group A <30 years and Group B >31 years.

Results: GLS was higher in females (P<0.01) and in Group A (P<0.01). On the contrary GCS and GRS were higher in men (P=NS) and in Group B (P<0.01), at the mitral valve level. At the papillary muscle level GCS and GRS values are more in men (P<0.01) and in <30 years of age (P<0.01 and P<0.05 respectively). Furthermore, the values of numerous other strain parameters-GLSR, GCSR, GRSR, LGV, TV, TS, TSR, Shear, Shear rate, ROV and RV, reflected heterogeneous variation across gender and various age groups. Twist was greater in men and increased with increasing age (P<0.01).

Conclusion: We have demonstrated a comprehensive data obtained in the current study utilizing 4D XStrain STE in healthy subjects. The LV speckle tracking software simultaneously provided 4D volumetric, strain, rotation and twist data in great detail. However, this distinctive technology has not been widely adopted and its evaluation is still limited to research applications. Therefore, further clinical studies are needed to validate our findings.

4D XStrain散斑跟踪超声心动图(STE)是一种可行的评价左心室应变和旋转变形的新技术。我们的目的是详尽地呈现2019冠状病毒病大流行期间印度健康成年人左室应变和扭转参数的正常值范围,并进一步分析其与年龄和性别的关系。方法:研究人群为80例18-60岁的成年人,其中男性58例,女性22例,随机分为两组:A组31岁。结果:GLS在女性中较高(p结论:我们证实了本研究在健康受试者中使用4D XStrain STE获得的全面数据。LV散斑跟踪软件同时提供了非常详细的四维体积,应变,旋转和扭转数据。然而,这一独特的技术尚未被广泛采用,其评价仍局限于研究应用。因此,需要进一步的临床研究来验证我们的发现。
{"title":"4 Dimensional XStrain speckle tracking echocardiography: comprehensive evaluation of left ventricular strain and twist parameters in healthy Indian adults during COVID-19 pandemic.","authors":"Akhil Mehrotra,&nbsp;Shubham Kacker,&nbsp;Mohammad Shadab,&nbsp;Naveen Chandra,&nbsp;Alok Kumar Singh","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>4D XStrain speckle tracking echocardiography (STE) is a feasible newer technology to evaluate the strain and rotational deformation of left ventricle (LV). We aimed to exhaustively present the normal value ranges of LV strain and twist parameter in healthy Indian adults during COVID-19 pandemic and furthermore to analyse their relationship with age and gender.</p><p><strong>Method: </strong>Study population consisted of 80 adults of 18-60 years (58 men, 22 women), which was arbitrarily divided into two groups: Group A <30 years and Group B >31 years.</p><p><strong>Results: </strong>GLS was higher in females (P<0.01) and in Group A (P<0.01). On the contrary GCS and GRS were higher in men (P=NS) and in Group B (P<0.01), at the mitral valve level. At the papillary muscle level GCS and GRS values are more in men (P<0.01) and in <30 years of age (P<0.01 and P<0.05 respectively). Furthermore, the values of numerous other strain parameters-GLSR, GCSR, GRSR, LGV, TV, TS, TSR, Shear, Shear rate, ROV and RV, reflected heterogeneous variation across gender and various age groups. Twist was greater in men and increased with increasing age (P<0.01).</p><p><strong>Conclusion: </strong>We have demonstrated a comprehensive data obtained in the current study utilizing 4D XStrain STE in healthy subjects. The LV speckle tracking software simultaneously provided 4D volumetric, strain, rotation and twist data in great detail. However, this distinctive technology has not been widely adopted and its evaluation is still limited to research applications. Therefore, further clinical studies are needed to validate our findings.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490166/pdf/ajcd0012-0192.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33478389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Determining the diagnostic value of three clinical criteria Wells', YEARS and modified Geneva in pregnant women with suspected pulmonary thromboembolism. 确定三项临床标准Wells、YEARS和改良Geneva对疑似肺血栓栓塞孕妇的诊断价值。
IF 1.3 Pub Date : 2022-08-15 eCollection Date: 2022-01-01
Somayeh Sadeghi, Parvin Bahrami, Sareh Kimiyaee Far, Zahra Arabi

Background: Diagnosis of pulmonary thromboembolism (PTE) during pregnancy is a challenging medical issue due to complications of X-ray-based imaging studies such as Ct-angiography for neonates and pregnant women. Here we aimed to assess the predictive values of three clinical criteria for diagnosing PTE during pregnancy.

Methods: This is a retrospective cohort study performed in 2018-2020 on 166 pregnant women suspected of PTE. We reviewed the documents of all patients referred to our medical center with suspected symptoms of PTE. The demographic characteristics of the patients, signs and clinical findings upon the arrival of patients as well as their laboratory tests including D-dimer with a history of abortion or delivery and leg symptoms were entered into the data collection form. Then, according to the information extracted from the patient's files, each patient was evaluated by all clinical PTE criteria, including Wells, YEARS and modified Geneva. For each patient according to clinical criteria and all three algorithms, clinical suspicion for PTE and treatment or non-treatment was determined were compared to the final MDCT result of patients.

Results: The Well's criteria had 100% sensitivity, 6.47% specificity, a positive predictive value of 7.8% and a negative predictive value of 100%. In patients with Well's score of more than four, the sensitivity and specificity of PTE diagnosis were 100% and 6% respectively. The modified Geneva criteria had 100% sensitivity, 8.89% specificity, a positive predictive value of 8.21% and a negative predictive value of 100%. The modified Geneva criteria had 100% sensitivity, 7.74% specificity, positive predictive value of 8.44% and a negative predictive value of 100%.

Conclusion: Wells, YEARS and modified Geneva criteria could significantly rule out PTE in pregnancy with 100% sensitivity.

背景:妊娠期间肺血栓栓塞(PTE)的诊断是一个具有挑战性的医学问题,因为基于x射线的影像学研究,如新生儿和孕妇的ct血管造影的并发症。在这里,我们旨在评估诊断妊娠PTE的三个临床标准的预测价值。方法:对2018-2020年166例疑似PTE孕妇进行回顾性队列研究,查阅所有就诊于我院疑似PTE患者的文献资料,将患者的人口学特征、患者来院时的体征、临床表现及实验室检测结果(包括流产或分娩史、腿部症状)录入数据收集表。然后,根据从患者档案中提取的信息,对每位患者进行所有临床PTE标准的评估,包括Wells、YEARS和modified Geneva。根据临床标准及三种算法对每例患者进行PTE的临床怀疑及治疗或不治疗,并与患者的最终MDCT结果进行比较。结果:Well标准的敏感性为100%,特异性为6.47%,阳性预测值为7.8%,阴性预测值为100%。Well’s评分大于4分的患者,诊断PTE的敏感性为100%,特异性为6%。修改后的日内瓦标准敏感性100%,特异性8.89%,阳性预测值8.21%,阴性预测值100%。改进的日内瓦标准敏感性100%,特异性7.74%,阳性预测值8.44%,阴性预测值100%。结论:Wells、YEARS及改良日内瓦标准均能明显排除妊娠PTE,敏感性100%。
{"title":"Determining the diagnostic value of three clinical criteria Wells', YEARS and modified Geneva in pregnant women with suspected pulmonary thromboembolism.","authors":"Somayeh Sadeghi,&nbsp;Parvin Bahrami,&nbsp;Sareh Kimiyaee Far,&nbsp;Zahra Arabi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Diagnosis of pulmonary thromboembolism (PTE) during pregnancy is a challenging medical issue due to complications of X-ray-based imaging studies such as Ct-angiography for neonates and pregnant women. Here we aimed to assess the predictive values of three clinical criteria for diagnosing PTE during pregnancy.</p><p><strong>Methods: </strong>This is a retrospective cohort study performed in 2018-2020 on 166 pregnant women suspected of PTE. We reviewed the documents of all patients referred to our medical center with suspected symptoms of PTE. The demographic characteristics of the patients, signs and clinical findings upon the arrival of patients as well as their laboratory tests including D-dimer with a history of abortion or delivery and leg symptoms were entered into the data collection form. Then, according to the information extracted from the patient's files, each patient was evaluated by all clinical PTE criteria, including Wells, YEARS and modified Geneva. For each patient according to clinical criteria and all three algorithms, clinical suspicion for PTE and treatment or non-treatment was determined were compared to the final MDCT result of patients.</p><p><strong>Results: </strong>The Well's criteria had 100% sensitivity, 6.47% specificity, a positive predictive value of 7.8% and a negative predictive value of 100%. In patients with Well's score of more than four, the sensitivity and specificity of PTE diagnosis were 100% and 6% respectively. The modified Geneva criteria had 100% sensitivity, 8.89% specificity, a positive predictive value of 8.21% and a negative predictive value of 100%. The modified Geneva criteria had 100% sensitivity, 7.74% specificity, positive predictive value of 8.44% and a negative predictive value of 100%.</p><p><strong>Conclusion: </strong>Wells, YEARS and modified Geneva criteria could significantly rule out PTE in pregnancy with 100% sensitivity.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490165/pdf/ajcd0012-0240.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33478392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 and preventive strategy. COVID-19和预防战略。
IF 1.3 Pub Date : 2022-08-15 eCollection Date: 2022-01-01
Chayakrit Krittanawong, Neil Maitra, Anirudh Kumar, Joshua Hahn, Zhen Wang, Daniela Carrasco, Hong Ju Zhang, Tao Sun, Hani Jneid, Salim S Virani

In December 2019, an unprecedented outbreak of the novel coronavirus disease 2019 (COVID-19), an infectious disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) began to spread internationally, now impacting more than 293,750,692 patients with 5,454,131 deaths globally as of January 5, 2022. COVID-19 is highly pathogenic and contagious which has caused a large-scale epidemic impacting more deaths than the severe acute respiratory syndrome (SARS) epidemic in 2002-2003 or the Middle East respiratory syndrome (MERS) epidemic in 2012-2013. Although COVID-19 symptoms are mild in most people, in those with pre-existing comorbidities there is an increased risk of progression to severe disease and death. In an attempt to mitigate this pandemic, urgent public health measures including quarantining exposed individuals and social distancing have been implemented in most states, while some states have even started the process of re-opening after considering both the economic and public health consequences of social distancing measures. While prevention is crucial, both novel agents and medications already in use with other indications are being investigated in clinical trials for patients with COVID-19. The collaboration between healthcare providers, health systems, patients, private sectors, and local and national governments is needed to protect both healthcare providers and patients to ultimately overcome this pandemic. The purpose of this review is to summarize the peer-reviewed and preprint literature on the epidemiology, transmission, clinical presentation, and available therapies as well as to propose a preventive strategy to overcome the present global pandemic.

2019年12月,由严重急性呼吸系统综合征冠状病毒-2 (SARS-CoV-2)引起的前所未有的新型冠状病毒病2019 (COVID-19)开始在国际上传播,截至2022年1月5日,全球共有293,750,692名患者受到影响,死亡人数为5,454,131人。COVID-19具有高致病性和传染性,已造成大规模流行,造成的死亡人数超过2002-2003年严重急性呼吸系统综合征(SARS)流行或2012-2013年中东呼吸综合征(MERS)流行。尽管大多数人的COVID-19症状较轻,但在已有合并症的患者中,进展为严重疾病和死亡的风险增加。为了缓解这次大流行,大多数州都采取了紧急公共卫生措施,包括隔离接触者和保持社会距离,有些州甚至在考虑了社会距离措施的经济和公共卫生后果后,开始了重新开放的进程。虽然预防至关重要,但正在对COVID-19患者进行临床试验,研究新型药物和已经用于其他适应症的药物。需要卫生保健提供者、卫生系统、患者、私营部门以及地方和国家政府之间的合作,以保护卫生保健提供者和患者,最终战胜这场大流行。本综述的目的是总结同行评审和预印本文献,包括流行病学、传播、临床表现和现有治疗方法,并提出克服当前全球大流行的预防策略。
{"title":"COVID-19 and preventive strategy.","authors":"Chayakrit Krittanawong,&nbsp;Neil Maitra,&nbsp;Anirudh Kumar,&nbsp;Joshua Hahn,&nbsp;Zhen Wang,&nbsp;Daniela Carrasco,&nbsp;Hong Ju Zhang,&nbsp;Tao Sun,&nbsp;Hani Jneid,&nbsp;Salim S Virani","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In December 2019, an unprecedented outbreak of the novel coronavirus disease 2019 (COVID-19), an infectious disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) began to spread internationally, now impacting more than 293,750,692 patients with 5,454,131 deaths globally as of January 5, 2022. COVID-19 is highly pathogenic and contagious which has caused a large-scale epidemic impacting more deaths than the severe acute respiratory syndrome (SARS) epidemic in 2002-2003 or the Middle East respiratory syndrome (MERS) epidemic in 2012-2013. Although COVID-19 symptoms are mild in most people, in those with pre-existing comorbidities there is an increased risk of progression to severe disease and death. In an attempt to mitigate this pandemic, urgent public health measures including quarantining exposed individuals and social distancing have been implemented in most states, while some states have even started the process of re-opening after considering both the economic and public health consequences of social distancing measures. While prevention is crucial, both novel agents and medications already in use with other indications are being investigated in clinical trials for patients with COVID-19. The collaboration between healthcare providers, health systems, patients, private sectors, and local and national governments is needed to protect both healthcare providers and patients to ultimately overcome this pandemic. The purpose of this review is to summarize the peer-reviewed and preprint literature on the epidemiology, transmission, clinical presentation, and available therapies as well as to propose a preventive strategy to overcome the present global pandemic.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490164/pdf/ajcd0012-0153.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33478390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of achieving euthyroidism on pulmonary artery systolic pressures in hyperthyroidism-associated pulmonary hypertension - a systematic review. 实现甲状腺功能亢进对甲亢相关性肺动脉高压患者肺动脉收缩压的影响——一项系统综述。
IF 1.3 Pub Date : 2022-08-15 eCollection Date: 2022-01-01
Shireen R Chacko, Pradhum Ram, Tamaryn Fox, Naveen Sooknanan, Kevin Bryan Lo, Ritesh G Menezes, Savita Lasrado, Glenn Eiger, Anjali Vaidya

In this systematic review, we seek to clarify the impact of treatment of hyperthyroidism on pulmonary hypertension in patients with both these conditions. We included 39 of 709 articles retrieved, that studied patients with hyperthyroidism and pulmonary hypertension (PH). From these, those with a documented pre-treatment Pulmonary Artery Systolic Pressure (PASP) > 35 mmHg and complete follow up were analyzed, yielding 3 case series and 22 case reports with a total of 81 cases. A significant improvement in PASP was noted with achieving euthyroidism in the 3 case series. The case reports showed a significant reduction in mean PASP from 60.5 ± 13.2 mmHg to 37.5 ± 10.1 mmHg (p < 0.001) in patients with Grave's disease with achieving euthyroidism. No deaths were reported during the follow up period. Achievement of a euthyroid state in patients with hyperthyroidism is associated with statistically significant reductions in PASP.

在这篇系统综述中,我们试图阐明甲状腺机能亢进治疗对合并这两种疾病的肺动脉高压患者的影响。我们在检索到的709篇研究甲状腺功能亢进和肺动脉高压(PH)患者的文章中纳入了39篇。从这些病例中,分析了治疗前记录的肺动脉收缩压(PASP) > 35 mmHg并完成随访的患者,得到3个病例系列和22个病例报告,共81例。在3例患者中,PASP显著改善,甲状腺功能恢复正常。病例报告显示,graves病患者的平均PASP从60.5±13.2 mmHg显著降低到37.5±10.1 mmHg (p < 0.001)。随访期间无死亡报告。甲亢患者达到甲状腺功能正常状态与PASP显著降低相关。
{"title":"Impact of achieving euthyroidism on pulmonary artery systolic pressures in hyperthyroidism-associated pulmonary hypertension - a systematic review.","authors":"Shireen R Chacko,&nbsp;Pradhum Ram,&nbsp;Tamaryn Fox,&nbsp;Naveen Sooknanan,&nbsp;Kevin Bryan Lo,&nbsp;Ritesh G Menezes,&nbsp;Savita Lasrado,&nbsp;Glenn Eiger,&nbsp;Anjali Vaidya","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In this systematic review, we seek to clarify the impact of treatment of hyperthyroidism on pulmonary hypertension in patients with both these conditions. We included 39 of 709 articles retrieved, that studied patients with hyperthyroidism and pulmonary hypertension (PH). From these, those with a documented pre-treatment Pulmonary Artery Systolic Pressure (PASP) > 35 mmHg and complete follow up were analyzed, yielding 3 case series and 22 case reports with a total of 81 cases. A significant improvement in PASP was noted with achieving euthyroidism in the 3 case series. The case reports showed a significant reduction in mean PASP from 60.5 ± 13.2 mmHg to 37.5 ± 10.1 mmHg (p < 0.001) in patients with Grave's disease with achieving euthyroidism. No deaths were reported during the follow up period. Achievement of a euthyroid state in patients with hyperthyroidism is associated with statistically significant reductions in PASP.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490158/pdf/ajcd0012-0212.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33478391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of supra coronary aortic repair technique in patients with acute aortic dissection type A. 冠状动脉上动脉修复技术治疗急性A型主动脉夹层的疗效。
IF 1.3 Pub Date : 2022-08-15 eCollection Date: 2022-01-01
Mahmood Saeidi, Minoo Movahedi, Aryan Rafiee Zadeh, Fahimeh Shirvany, Milad Saeidi

Background: Acute aortic dissection type A (AADA) is a fatal event that requires an emergent surgical operation. Here, we decided to evaluate the outcome of supra coronary aortic repair technique in patients with type A acute aortic dissection for 16 years in Isfahan Chamran hospital that one surgeon performed.

Methods: This is a retrospective descriptive cross-sectional study performed in 2019 in Isfahan on documents of 54 patients who underwent supra-coronary repair surgery for type A aortic dissection during 2004 to 2019. We collected patient's demographic information, the condition of patient's vital signs at the time of admission to the hospital and before surgery, the cardiopulmonary bypass (CPB) time and other variables. We also collected data regarding patient's mortality and possible surgical complications.

Results: Evaluation of surgical complications showed that acute renal failure (ARF) was the most common complication (87%) followed by postoperative bleeding in ICU that required surgical operation (18.5%), neurologic complications (13%), acute respiratory distress syndrome (ARDS) (9.3%) and chronic renal failure (CRF) (1.9%). The mortality rate was 14.8% (8 patients). The most frequent reason for mortality was bleeding (50%), major neurologic complications (37.5%), multiple organ failure (25%), cardiac failure (12.5%) and CRF (12.5%). Patients with mortality had significantly higher age compared to other patients (P = 0.03), significantly higher duration of CPB use (P = 0.03), higher frequency of irregular peripheral pulses (P = 0.01), higher frequency of abnormal carotid pulses (P = 0.04), and higher bleeding volume in the ICU (P = 0.04).

Conclusion: Age, disturbed preoperative clinical condition, postoperative bleeding, and organ failure could increase the rates of mortality of AADA.

背景:急性主动脉夹层A型(AADA)是一种需要紧急外科手术的致命事件。在这里,我们决定评估冠状动脉上动脉修复技术在伊斯法罕Chamran医院一名外科医生进行的16年A型急性主动脉夹层患者中的效果。方法:这是一项回顾性描述性横断面研究,于2019年在伊斯法罕进行,研究对象是2004年至2019年期间因a型主动脉夹层接受冠状动脉上修复手术的54例患者。收集患者的人口学信息、入院时及术前患者生命体征情况、体外循环时间等变量。我们还收集了有关患者死亡率和可能的手术并发症的数据。结果:对手术并发症的评估显示,急性肾功能衰竭(ARF)是最常见的并发症(87%),其次是ICU术后出血(18.5%)、神经系统并发症(13%)、急性呼吸窘迫综合征(ARDS)(9.3%)和慢性肾功能衰竭(CRF)(1.9%)。死亡率为14.8%(8例)。最常见的死亡原因是出血(50%)、主要神经系统并发症(37.5%)、多器官功能衰竭(25%)、心力衰竭(12.5%)和慢性肾功能衰竭(12.5%)。死亡率患者年龄明显高于其他患者(P = 0.03), CPB使用时间明显高于其他患者(P = 0.03),外周脉搏不规则频率显著高于其他患者(P = 0.01),颈动脉脉搏异常频率显著高于其他患者(P = 0.04), ICU出血量显著高于其他患者(P = 0.04)。结论:年龄、术前临床状况不佳、术后出血、脏器功能衰竭等因素可增加AADA患者的死亡率。
{"title":"Outcomes of supra coronary aortic repair technique in patients with acute aortic dissection type A.","authors":"Mahmood Saeidi,&nbsp;Minoo Movahedi,&nbsp;Aryan Rafiee Zadeh,&nbsp;Fahimeh Shirvany,&nbsp;Milad Saeidi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Acute aortic dissection type A (AADA) is a fatal event that requires an emergent surgical operation. Here, we decided to evaluate the outcome of supra coronary aortic repair technique in patients with type A acute aortic dissection for 16 years in Isfahan Chamran hospital that one surgeon performed.</p><p><strong>Methods: </strong>This is a retrospective descriptive cross-sectional study performed in 2019 in Isfahan on documents of 54 patients who underwent supra-coronary repair surgery for type A aortic dissection during 2004 to 2019. We collected patient's demographic information, the condition of patient's vital signs at the time of admission to the hospital and before surgery, the cardiopulmonary bypass (CPB) time and other variables. We also collected data regarding patient's mortality and possible surgical complications.</p><p><strong>Results: </strong>Evaluation of surgical complications showed that acute renal failure (ARF) was the most common complication (87%) followed by postoperative bleeding in ICU that required surgical operation (18.5%), neurologic complications (13%), acute respiratory distress syndrome (ARDS) (9.3%) and chronic renal failure (CRF) (1.9%). The mortality rate was 14.8% (8 patients). The most frequent reason for mortality was bleeding (50%), major neurologic complications (37.5%), multiple organ failure (25%), cardiac failure (12.5%) and CRF (12.5%). Patients with mortality had significantly higher age compared to other patients (P = 0.03), significantly higher duration of CPB use (P = 0.03), higher frequency of irregular peripheral pulses (P = 0.01), higher frequency of abnormal carotid pulses (P = 0.04), and higher bleeding volume in the ICU (P = 0.04).</p><p><strong>Conclusion: </strong>Age, disturbed preoperative clinical condition, postoperative bleeding, and organ failure could increase the rates of mortality of AADA.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490162/pdf/ajcd0012-0247.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33477982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early reversibility of histological changes after experimental acute cardiac volume-overload. 实验性急性心脏容量过载后组织学改变的早期可逆性。
IF 1.3 Pub Date : 2022-08-15 eCollection Date: 2022-01-01
Christa Huuskonen, Mari Hämäläinen, Nooa Kivikangas, Timo Paavonen, Eeva Moilanen, Ari A Mennander

Unloading the heart may aid recovery after acute cardiac volume-overload (AVO). We experimentally investigated whether unloading the heart after AVO by heterotopic transplantation histologically impacts myocardial outcome. Thirty-two syngeneic Fisher 344 rats underwent surgery for abdominal arterial-venous fistula to induce AVO. Seven hearts were heterotopically transplanted one day after AVO to simulate a non-working state of the left ventricle (AVO+Tx). In addition, six rats without AVO or surgery (Normal) and five rats with sham surgery (Sham) served as controls. Myocardial outcome was studied using histology and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis for hypoxia inducible factor 1alpha (HIF1α), inducible nitric oxide synthase (iNOS), E-selectin, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), vascular endothelial growth factor alpha (VEGFα), matrix metalloprotease 9 (MMP9), chitinase-3-like protein (YKL-40) and transforming growth factor beta (TGFβ). Relative ischemia of the right ventricle and septal intramyocardial arteries was decreased in AVO+Tx as compared with AVO (0.04±0.01 vs. 0.09±0.02, PSU, P=0.040 and 0.04±0.01 vs. 0.16±0.02, PSU, P=0.008, respectively). Quantitative RT-PCR showed an increase in the expression of iNOS, YKL-40 and VEGFα, and decrease in ANP in AVO+Tx as compared with AVO (5.78±1.23 vs. 2.46±0.81, P=0.039, 22.39±5.22 vs. 10.79±1.70, P=0.039 and 1.15±0.22 vs. 0.60±0.08, P=0.030, and 1.32±0.16 vs. 2.85±0.70, P=0.039, respectively). Unloading the heart by heterotopic transplantation induces early ischemic recovery of intramyocardial arteries after AVO. A non-working state reverses acute ischemic myocardial injury after AVO.

卸载心脏可能有助于急性心脏容量过载(AVO)后的恢复。我们通过实验研究了异位心脏移植对AVO术后心肌预后的组织学影响。32只同基因Fisher 344大鼠腹腔动静脉瘘手术诱导AVO。7颗心脏在AVO术后1天异位移植,模拟左心室非工作状态(AVO+Tx)。另外,6只未做AVO或手术的大鼠(Normal)和5只做假手术的大鼠(sham)作为对照。采用组织学和定量反转录聚合酶链反应(qRT-PCR)分析缺氧诱导因子1α (HIF1α)、诱导型一氧化氮合酶(iNOS)、e-选择素、房利钠肽(ANP)、脑利钠肽(BNP)、血管内皮生长因子α (VEGFα)、基质金属蛋白酶9 (MMP9)、几丁质酶3样蛋白(YKL-40)和转化生长因子β (TGFβ)。与AVO组相比,AVO+Tx组右心室和心间隔动脉相对缺血减少(分别为0.04±0.01比0.09±0.02,PSU, P=0.040和0.04±0.01比0.16±0.02,PSU, P=0.008)。定量RT-PCR结果显示,与AVO组相比,AVO+Tx组iNOS、YKL-40和VEGFα表达增加(5.78±1.23比2.46±0.81,P=0.039; 22.39±5.22比10.79±1.70,P=0.039; 1.15±0.22比0.60±0.08,P=0.030; 1.32±0.16比2.85±0.70,P=0.039)。异位移植卸载心脏可诱导AVO术后心肌内动脉早期缺血恢复。非工作状态可逆转AVO后急性缺血性心肌损伤。
{"title":"Early reversibility of histological changes after experimental acute cardiac volume-overload.","authors":"Christa Huuskonen,&nbsp;Mari Hämäläinen,&nbsp;Nooa Kivikangas,&nbsp;Timo Paavonen,&nbsp;Eeva Moilanen,&nbsp;Ari A Mennander","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Unloading the heart may aid recovery after acute cardiac volume-overload (AVO). We experimentally investigated whether unloading the heart after AVO by heterotopic transplantation histologically impacts myocardial outcome. Thirty-two syngeneic Fisher 344 rats underwent surgery for abdominal arterial-venous fistula to induce AVO. Seven hearts were heterotopically transplanted one day after AVO to simulate a non-working state of the left ventricle (AVO+Tx). In addition, six rats without AVO or surgery (Normal) and five rats with sham surgery (Sham) served as controls. Myocardial outcome was studied using histology and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis for hypoxia inducible factor 1alpha (HIF1α), inducible nitric oxide synthase (iNOS), E-selectin, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), vascular endothelial growth factor alpha (VEGFα), matrix metalloprotease 9 (MMP9), chitinase-3-like protein (YKL-40) and transforming growth factor beta (TGFβ). Relative ischemia of the right ventricle and septal intramyocardial arteries was decreased in AVO+Tx as compared with AVO (0.04±0.01 vs. 0.09±0.02, PSU, <i>P</i>=0.040 and 0.04±0.01 vs. 0.16±0.02, PSU, P=0.008, respectively). Quantitative RT-PCR showed an increase in the expression of iNOS, YKL-40 and VEGFα, and decrease in ANP in AVO+Tx as compared with AVO (5.78±1.23 vs. 2.46±0.81, <i>P</i>=0.039, 22.39±5.22 vs. 10.79±1.70, <i>P</i>=0.039 and 1.15±0.22 vs. 0.60±0.08, <i>P</i>=0.030, and 1.32±0.16 vs. 2.85±0.70, <i>P</i>=0.039, respectively). Unloading the heart by heterotopic transplantation induces early ischemic recovery of intramyocardial arteries after AVO. A non-working state reverses acute ischemic myocardial injury after AVO.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490159/pdf/ajcd0012-0205.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33477986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American journal of cardiovascular disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1